Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Elevance Health (ELV) is 7/10.
Elevance reported Q1 2026 operating revenue of $49.5B, up 1.5%, with adjusted EPS of $12.58 as Medicaid cost trend actions gained early traction. Management raised FY2026 adjusted EPS guidance to at least $26.75 from at least $25.50, though approximately $1.00 of the $1.25 increase reflected nonrecurring investment valuation adjustments. The CMS risk adjustment data accrual reached $935M, and the commercial selling season pipeline stood at record levels.
Scored from Elevance Health’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $45.44B | +6.6% | $1.81 | -50.1% | 2.1% | 0.9% | $384M |
| FY2025 Q1 | $48.89B | +14.8% | $9.61 | +0.2% | 6.4% | 4.5% | $821M |
| FY2025 Q2 | $49.78B | +14.0% | $7.72 | -21.6% | 5.3% | 3.5% | $1.79B |
| FY2025 Q3 | $50.71B | +12.3% | $5.32 | +22.0% | 3.5% | 2.3% | $775M |
| FY2025 Q4 | $49.75B | +9.5% | $2.47 | +36.5% | 1.2% | 1.1% | $-209M |
| FY2026 Q1 | $50.18B | +2.6% | $8.00 | -16.8% | 5.3% | 3.5% | $4.10B |
| FY2026 Q2 | $50.47B | +1.4% | $6.71 | -13.1% | 4.1% | 2.9% | $1.63B |
Reported Thursday, Jul 16. Earnings call pending.
A pre-earnings brief is ready for ELV: the setup, what peers and partners said this season, and which analysts to watch. Reading it is a Tellvest Pro feature.